Norbert Riedel, Ph.D.

Senior Executive Advisor

Norbert Riedel, Ph.D.

Senior Executive Advisor

 
Since September 2015, Dr. Riedel has served as Chief Executive Officer and President of Aptinyx, Inc., a biopharmaceutical company that spun out of its predecessor, Naurex, Inc. Dr. Riedel served as Chief Executive Officer and President of Naurex, Inc. from January 2014 to September 2015.
From 2001 to 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company. From 1998 to 2001, he was President and General Manager of Baxter’s recombinant therapeutic proteins business unit and Vice President of research and development of the bioscience business unit. Prior to that, Dr. Riedel served as head of worldwide biotechnology and core research functions at Hoechst-Marion Roussel (now Sanofi), a global pharmaceutical company, from 1996 to 1998. Additionally, Dr. Riedel was a member of the Board of Directors for Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017.

Dr. Riedel currently serves on the Board of Directors of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and the Illinois Biotechnology Industry Organization. He is a member of the Austrian Academy of Sciences as well as an adjunct professor at both Boston University’s School of Medicine and Northwestern University’s Feinberg School of Medicine.

Dr. Riedel holds a diploma in biochemistry and received a Ph.D. degree in biochemistry from the University of Frankfurt.